GlassScriptPhysician profile
Laxmi Dhakal
NPI 1598997348
$4,238.40
in general payments reported to CMS, 2019-2025
30 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,875 · 2020: $779 · 2021: $166 · 2022: $31.76 · 2023: $13.33 · 2024: $267 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,353.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $409.68 | 2019-2021 | |
| Biogen, INC. | $321.97 | 2019-2020 | |
| Amgen INC. | $274.32 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $223.95 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $208.61 | 2019-2020 | |
| Atricure, INC. | $154.27 | 2024 | |
| Emd Serono, INC. | $151.67 | 2019-2020 | |
| Microvention, INC. | $126.92 | 2019 | |
| Allergan, INC. | $115.88 | 2019-2020 | |
| Abiomed | $113.03 | 2024 | Impella |
| Ceribell, INC. | $106.25 | 2025 | Pocket Eeg Device |
| Ucb, INC. | $80.02 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $79.02 | 2019-2020 | |
| Genzyme Corporation | $63.65 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $55.19 | 2020-2021 | |
| Lundbeck LLC | $52.17 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $45.21 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $38.76 | 2019-2020 | |
| Lilly USA, LLC | $37.98 | 2019-2020 | |
| Kyowa Kirin, INC. | $36.19 | 2020 | |
| Genentech USA, INC. | $30.35 | 2020 | |
| Abbvie INC. | $29.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $26.37 | 2019 | |
| Avanir Pharmaceuticals, INC. | $22.57 | 2019 | |
| Amneal Pharmaceuticals LLC | $18.83 | 2020 | |
| Greenwich Biosciences, INC. | $18.28 | 2021 | |
| Tanabe Pharma America, INC. | $17.91 | 2019 | |
| Eisai INC. | $13.66 | 2019 | |
| Acadia Pharmaceuticals INC | $13.33 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laxmi Dhakal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.